Coronary artery calcium score as a gatekeeper for further testing in patients with low pretest probability of obstructive coronary artery disease: A cost-effectiveness analysis

被引:4
作者
Gomes, Daniel A. [1 ]
Lopes, Pedro M. [1 ]
Albuquerque, Francisco [1 ]
Freitas, Pedro [1 ,3 ]
Silva, Claudia [1 ]
Guerreiro, Sara [1 ]
Abecasis, Joao [1 ]
Santos, Ana Coutinho [2 ,3 ]
Saraiva, Carla [2 ]
Ferreira, Jorge [1 ]
Goncalves, Pedro de Araujo [1 ,3 ]
Marques, Hugo [1 ,3 ]
Mendes, Miguel [1 ]
Ferreira, Antonio M. [1 ,3 ]
机构
[1] Hosp Santa Cruz, Ctr Hosp Lisboa Ocidental, Dept Cardiol, Lisbon, Portugal
[2] Hosp Santa Cruz, Ctr Hosp Lisboa Ocidental, Dept Radiol, Lisbon, Portugal
[3] Hosp Luz, UNICA Cardiovasc CT & MR Unit, Lisbon, Portugal
关键词
Cost-effectiveness; Coronary artery disease; Diagnosis; Coronary artery calcium score; Coronary CT angiography; COMPUTED-TOMOGRAPHY; ANGIOGRAPHY; LIKELIHOOD; DIAGNOSIS; SOCIETY;
D O I
10.1016/j.repc.2023.03.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction and objectives: Current guidelines recommend not routinely testing patients with chest pain and low pretest probability (PTP <15%) of obstructive coronary artery disease (CAD), but envisage the use of risk modifiers, such as coronary artery calcium score (CACS), to refine patient selection for testing. We aimed to assess the cost-effectiveness (CE) of three different testing strategies in this population: (A) defer testing; (B) perform CACS, withholding further testing if CACS=0, and proceeding to coronary CT angiography (CCTA) if CACS>0; (C) CCTA in all. Methods: We developed a CE model using data from a two-center cross-sectional study of 1385 patients with non-acute chest pain and PTP <15% undergoing CACS followed by CCTA. Key input data included the prevalence of obstructive CAD on CCTA (10.3%), the proportion with CACS=0 (57%), and the negative predictive value of CACS for obstructive CAD on CCTA (98.1%). Results: Not testing would correctly classify 89.7% of cases and at a cost of euro 121 433 per 1000 patients. Using CACS as a gatekeeper for CCTA would correctly diagnose 98.9% of cases and cost euro 247 116/1000 patients. Employing first-line CCTA would correctly classify all patients, at a cost of euro 271 007/1000 diagnosed patients. The added cost for an additional correct diagnosis was euro 1366 for CACS & PLUSMN;CCTA vs. no testing, and euro 2172 for CCTA vs. CACS & PLUSMN;CCTA. Conclusions: CACS as a gatekeeper for further testing is cost-effective between a threshold of euro 1366 and euro 2172 per additional correct diagnosis. CCTA yields the most correct diagnoses and is cost-effective above a threshold of euro 2172. & COPY; 2023 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espan & SIM;a, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
引用
收藏
页码:617 / 624
页数:8
相关论文
共 31 条
  • [1] SCCT guidelines for the performance and acquisition of coronary computed tomographic angiography: A report of the society of Cardiovascular Computed Tomography Guidelines Committee Endorsed by the North American Society for Cardiovascular Imaging (NASCI)
    Abbara, Suhny
    Blanke, Philipp
    Maroules, Christopher D.
    Cheezum, Michael
    Choi, Andrew D.
    Han, B. Kelly
    Marwan, Mohamed
    Naoum, Chris
    Norgaard, Bjarne L.
    Rubinshtein, Ronen
    Schoenhagen, Paul
    Villines, Todd
    Leipsic, Jonathon
    [J]. JOURNAL OF CARDIOVASCULAR COMPUTED TOMOGRAPHY, 2016, 10 (06) : 435 - 449
  • [2] QUANTIFICATION OF CORONARY-ARTERY CALCIUM USING ULTRAFAST COMPUTED-TOMOGRAPHY
    AGATSTON, AS
    JANOWITZ, WR
    HILDNER, FJ
    ZUSMER, NR
    VIAMONTE, M
    DETRANO, R
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 15 (04) : 827 - 832
  • [3] Safety and Risk of Major Complications With Diagnostic Cardiac Catheterization
    Al-Hijji, Mohammed A.
    Lennon, Ryan J.
    Gulati, Rajiv
    El Sabbagh, Abdallah
    Park, Jae Yoon
    Crusan, Daniel
    Kanwar, Amrit
    Behfar, Atta
    Lerman, Amir
    Holmes, David R.
    Bell, Malcolm
    Singh, Mandeep
    [J]. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2019, 12 (07)
  • [4] Sex Differences in Coronary Artery Calcium and Long-term CV Mortality
    Bigeh, Allison
    Shekar, Chandana
    Gulati, Martha
    [J]. CURRENT CARDIOLOGY REPORTS, 2020, 22 (04)
  • [5] Biondi MJ, 2021, CIRCULATION, V144
  • [6] Cost effectiveness of coronary angiography and calcium scoring using CT and stress MRI for diagnosis of coronary artery disease
    Dewey, Marc
    Hamm, Bernd
    [J]. EUROPEAN RADIOLOGY, 2007, 17 (05) : 1301 - 1309
  • [7] Direct costs and cost-effectiveness of dual-source computed tomography and invasive coronary angiography in patients with an intermediate pretest likelihood for coronary artery disease
    Dorenkamp, Marc
    Bonaventura, Klaus
    Sohns, Christian
    Becker, Christoph R.
    Leber, Alexander W.
    [J]. HEART, 2012, 98 (06) : 460 - 467
  • [8] Cost-Effectiveness of Different Diagnostic Strategies in Suspected Stable Coronary Artery Disease in Portugal
    Ferreira, Antonio Miguel
    Marques, Hugo
    Goncalves, Pedro Araujo
    Cardim, Nuno
    [J]. ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2014, 102 (04) : 391 - 401
  • [9] Pretest probability for patients with suspected obstructive coronary artery disease: re-evaluating Diamond-Forresterfor the contemporary era and clinical implications: insights from the PROMISE trial
    Foldyna, Borek
    Udelson, James E.
    Karady, Julia
    Banerji, Dahlia
    Lu, Michael T.
    Mayrhofer, Thomas
    Bittner, Daniel O.
    Meyersohn, Nandini M.
    Emami, Hamed
    Genders, Tessa S. S.
    Fordyce, Christopher B.
    Ferencik, Maros
    Douglas, Pamela S.
    Hoffmann, Udo
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2019, 20 (05) : 574 - 581
  • [10] Diagnosis of obstructive coronary artery disease using computed tomography angiography in patients with stable chest pain depending on clinical probability and in clinically important subgroups: meta-analysis of individual patient data
    Haase, Robert
    Schlattmann, Peter
    Gueret, Pascal
    Andreini, Daniele
    Pontone, Gianluca
    Alkadhi, Hatem
    Hausleiter, Joerg
    Garcia, Mario J.
    Leschka, Sebastian
    Meijboom, Willem B.
    Zimmermann, Elke
    Gerber, Bernhard
    Schoepf, U. Joseph
    Shabestari, Abbas A.
    Norgaard, Bjarne L.
    Meijs, Matthijs F. L.
    Sato, Akira
    Ovrehus, Kristian A.
    Diederichsen, Axel C. P.
    Jenkins, Shona M. M.
    Knuuti, Juhani
    Hamdan, Ashraf
    Halvorsen, Bjorn A.
    Mendoza-Rodriguez, Vladimir
    Rochitte, Carlos E.
    Rixe, Johannes
    Wan, Yung Liang
    Langer, Christoph
    Bettencourt, Nuno
    Martuscelli, Eugenio
    Ghostine, Said
    Buechel, Ronny R.
    Nikolaou, Konstantin
    Mickley, Hans
    Yang, Lin
    Zhang, Zhaqoi
    Chen, Marcus Y.
    Halon, David A.
    Rief, Matthias
    Sun, Kai
    Hirt-Moch, Beatrice
    Niinuma, Hiroyuki
    Marcus, Roy P.
    Muraglia, Simone
    Jakamy, Reda
    Chow, Benjamin J.
    Kaufmann, Philipp A.
    Tardif, Jean-Claude
    Nomura, Cesar
    Kofoed, Klaus F.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2019, 365